Clinical trial
A Prospective, Multicenter, Open Label, Randomized, Controlled Clinical Study Evaluating the Effect of NovoSorb ® SynPath™ Dermal Matrix Compared to Standard of Care (SOC) In the Treatment of Nonresponsive, Chronic Diabetic Foot Ulcers.
NCT05506215 is registered in ClinicalTrials.gov with PolyNovo Biomaterials Pty Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicenter, Open Label, Randomized, Controlled Clinical Study Evaluating the Effect of NovoSorb ® SynPath™ Dermal Matrix Compared to Standard of Care (SOC) In the Treatment of Nonresponsive, Chronic Diabetic Foot Ulcers.
- Lead sponsor
- PolyNovo Biomaterials Pty Ltd.
- Phase
- Not applicable
- Overall status
- Terminated
- Start date
- July 10, 2022
- Completion date
- February 26, 2024
- Enrollment
- 25 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
chronic foot ulcer, diabetic foot, foot ulcer, wound healing